News Novo hopes hypoglycaemia data will boost Tresiba Lower severe hypo risk compared with Lantus - but no cardiac benefit.
News AZ’s Bydureon disappoints in diabetes outcomes trial Results give advantage to Boehringer/Lilly's Jardiance.
News Semaglutide could transform diabetes treatment, revive Novo ... Oral formulation of GLP-1 drug could help cut heart attacks, tackle liver and kidney problems
News Novo Nordisk board member quits over NASH conflict of intere... Mary Szela has quit to avoid a conflict of interest.
News Novo enjoys strong Q1 as Trump price crackdown fails to mate... Novo Nordisk has shaken off fears of a drug pricing crackdown from president Donald Trump, after it beat profit forecasts in Q1 results.
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
